Total Payments
$33,027
2024 Payments
$20,084
Companies
8
Transactions
29
Payment Breakdown by Category
Consulting$30,000 (90.8%)
Research$2,691 (8.1%)
Food & Beverage$335.72 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $30,000 | 4 | 90.8% |
| Unspecified | $2,691 | 17 | 8.1% |
| Food and Beverage | $335.72 | 8 | 1.0% |
Payments by Type
General
$30,336
12 transactions
Research
$2,691
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $20,000 | 2 | $0 (2024) |
| Sage Therapeutics, Inc. | $10,058 | 3 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,464 | 14 | $0 (2019) |
| Allergan Inc. | $226.48 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $125.00 | 1 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $68.27 | 4 | $0 (2017) |
| Medtronic, Inc. | $49.95 | 1 | $0 (2024) |
| ABBVIE INC. | $34.16 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,084 | 4 | Biogen, Inc. ($20,000) |
| 2023 | $183.34 | 2 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2022 | $10,000 | 2 | Sage Therapeutics, Inc. ($10,000) |
| 2019 | $2,691 | 17 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,464) |
| 2017 | $68.27 | 4 | Sunovion Pharmaceuticals Inc. ($68.27) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/24/2024 | Biogen, Inc. | ZURZUVAE (Drug) | Consulting Fee | Cash or cash equivalent | $10,000.00 | General |
| Category: Neurology | ||||||
| 05/21/2024 | Medtronic, Inc. | NELLCOR (Device) | Food and Beverage | In-kind items and services | $49.95 | General |
| Category: Pulse Oximetry | ||||||
| 05/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $34.16 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,000.00 | General |
| 09/08/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $58.34 | General |
| 02/08/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 02/03/2022 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 01/27/2022 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $186.19 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $157.96 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $60.00 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $35.00 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $7.55 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $631.60 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $125.00 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD • Category: PSYCHIATRY | ||||||
| 10/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $201.71 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $620.56 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $128.75 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $124.99 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 09/27/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY (Drug) | — | In-kind items and services | $85.04 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER • Category: PSYCHIATRY | ||||||
| 05/06/2019 | Allergan Inc. | VRAYLAR (Drug) | — | In-kind items and services | $123.47 | Research |
| Study: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment • Category: NEUROSCIENCE | ||||||
| 04/12/2019 | Allergan Inc. | VRAYLAR (Drug) | — | In-kind items and services | $80.96 | Research |
| Study: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment • Category: NEUROSCIENCE | ||||||
| 04/12/2019 | Allergan Inc. | VRAYLAR (Drug) | — | In-kind items and services | $22.05 | Research |
| Study: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment • Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,253 | 8 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,126 | 5 |
| A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment | Allergan Inc. | $226.48 | 3 |
| A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $85.04 | 1 |
About Dr. Judith Joseph, M.D
Dr. Judith Joseph, M.D is a Psychiatry healthcare provider based in Paterson, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1841487014.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Judith Joseph, M.D has received a total of $33,027 in payments from pharmaceutical and medical device companies, with $20,084 received in 2024. These payments were reported across 29 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($30,000).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Paterson, NJ
- Active Since 10/01/2007
- Last Updated 01/16/2015
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841487014
Products in Payments
- ZURZUVAE (Drug) $10,000
- REXULTI (Drug) $1,253
- VRAYLAR (Drug) $260.64
- BREZTRI (Drug) $125.00
- ABILIFY (Drug) $85.04
- LATUDA (Drug) $68.27
- NELLCOR (Device) $49.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Paterson
Dr. Nieves Cuervo, Md, MD
Psychiatry — Payments: $2,555
Psychiatry $2,555
Yuliya Dementyeva, Md, MD
Psychiatry — Payments: $728.87
Psychiatry $728.87
Louis Arroyo, M.d, M.D
Psychiatry — Payments: $680.98
Psychiatry $680.98
Marcia Ribalta, M.d, M.D
Psychiatry — Payments: $670.51
Psychiatry $670.51
Lauren Laporta, Md, MD
Psychiatry — Payments: $296.44
Psychiatry $296.44
Dr. Gamal Gad, M.d, M.D
Psychiatry — Payments: $251.11
Psychiatry $251.11